Home SpayVac™
for
Wildlife 		About
SpayVac™		 How
Spayvac™
Works		 FDA
Requirements		 About
Spayvac.org		 FAQ Contact

The way forward

The Project Team
In pursuing FDA approval for SpayVac™, SFW is undertaking the same type of job that a pharmaceutical company would undertake. To achieve our goal, we will employ an experienced team of specialists 1) to provide ongoing scientific expertise and 2) to assist in negotiating the maze of regulatory requirements. In addition to the involvement of scientists who have been key in the research and development of SpayVac™, we are in discussion with a consulting group that has the critical pharmaceutical development and registration expertise. Key project team members are:

SpayVac™-for-Wildlife, Inc. (SFW):

  • Mark A. Fraker (M.A., Zoology, Botany, Chemistry, President / Treasurer, SFW) conducted the Fallow Deer research in Canada and helped to initiate trials of SpayVac™ on White-tailed Deer in several US locations. A practicing biologist for >30 years, Mr. Fraker will have overall responsibility for coordinating the SpayVac™ Team, developing a fund-raising program to cover the costs of regulatory trials, and developing cooperative arrangements with potential collaborators.
  • Robert L. Cervelli, (M.Sc. Forestry, Botany, Vice-President / Secretary, SFW) is a founder and VP, Product Development, for IVT. With over 16 years’ experience as a life sciences business executive and a successful track record in biotechnology company management, Mr. Cervelli will oversee the commercialization of SpayVac™, including manufacturing, distribution, and market acceptance, as well as assisting with public relations and fund raising.

ImmunoVaccine Technologies, Inc.:

  • Robert G. Brown (B.Sc., Ph.D., Microbiology) was George S. Campbell Professor of Cellular Biology at Dalhousie University and is currently Chief Science Officer, IVT. As leader of the original research team, Dr. Brown has participated in all aspects of SpayVac™’s development, including vaccine formulation, field trials, and basic studies of the liposome technology that underlies SpayVac™’s extraordinary performance.

Pharmaceutical Industry Consultants:
The consulting group selected will be thoroughly experienced regarding FDA requirements and pharmaceutical industry manufacturing and testing practices.

Funding Sources
To keep the cost of SpayVac™ low enough to encourage its use, we are seeking charitable contributions to fund the FDA-approval process. Potential sources include:

  • Foundations with an interest in animal welfare and/or biodiversity,
  • Insurance companies, which pay millions of dollars in deer-collision claims,
  • Interested individuals in communities with overabundant deer,
  • Animal health companies interested in good will generated by such a project, and
  • Government agencies, such as the USDA’s National Wildlife Research Center.